Search research articles
Contact Us
Filters
Showing results (21-30 of 232) with videos related to
Page
of 24
Sort By:
Expert Review of Hematology
|
May 22, 2015
Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?
Hans Carl Hasselbalch, Richard T Silver
Leukemia
|
April 8, 2026
A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha
Richard T Silver, Hans Carl Hasselbalch
Expert Review of Hematology
|
April 4, 2023
Polycythemia vera: aspects of its current diagnosis and initial treatment
Richard T Silver, Ghaith Abu-Zeinah
Medical Journal (Fort Sam Houston, Tex.)
|
April 12, 2023
A Review of Intermittent Fasting as a Treatment for Type 2 Diabetes Mellitus
Derek T Silver, Timothy B Pekari
Hematology (Amsterdam, Netherlands)
|
February 23, 2016
Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials
Richard T Silver, Hans Carl Hasselbalch
Archives of Internal Medicine
|
January 1, 1977
Value of biopsy in diagnosis of primary lymphosarcoma of marrow
M Pasmantier, M Coleman, R T Silver
Immunological Reviews
|
August 22, 2001
Specificity and function of activating Ly-49 receptors
K P Kane, E T Silver, B Hazes
BMJ (Clinical Research Ed.)
|
January 13, 1996
Vocational training for general practice in inner London. Is there a dearth? And if so what's to be done?
T Harris, T Silver, E Rink, et al.
American Family Physician
|
January 1, 1975
Diagnosis of plasma cell myeloma
M W Pasmantier, M Coleman, R T Silver
Expert Review of Hematology
|
November 12, 2019
Myelofibrosis: best practices, controversies and 2019 update
Nicole M Cruz, Usama Gergis, Richard T Silver
Page
of 24
Search research articles
Search
Showing results (21-30 of 232) with videos related to
Sort By:
Page
of 24
Expert Review of Hematology
|
May 22, 2015
Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?
Hans Carl Hasselbalch, Richard T Silver
Leukemia
|
April 8, 2026
A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha
Richard T Silver, Hans Carl Hasselbalch
Expert Review of Hematology
|
April 4, 2023
Polycythemia vera: aspects of its current diagnosis and initial treatment
Richard T Silver, Ghaith Abu-Zeinah
Medical Journal (Fort Sam Houston, Tex.)
|
April 12, 2023
A Review of Intermittent Fasting as a Treatment for Type 2 Diabetes Mellitus
Derek T Silver, Timothy B Pekari
Hematology (Amsterdam, Netherlands)
|
February 23, 2016
Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials
Richard T Silver, Hans Carl Hasselbalch
Archives of Internal Medicine
|
January 1, 1977
Value of biopsy in diagnosis of primary lymphosarcoma of marrow
M Pasmantier, M Coleman, R T Silver
Immunological Reviews
|
August 22, 2001
Specificity and function of activating Ly-49 receptors
K P Kane, E T Silver, B Hazes
BMJ (Clinical Research Ed.)
|
January 13, 1996
Vocational training for general practice in inner London. Is there a dearth? And if so what's to be done?
T Harris, T Silver, E Rink, et al.
American Family Physician
|
January 1, 1975
Diagnosis of plasma cell myeloma
M W Pasmantier, M Coleman, R T Silver
Expert Review of Hematology
|
November 12, 2019
Myelofibrosis: best practices, controversies and 2019 update
Nicole M Cruz, Usama Gergis, Richard T Silver
Page
of 24